Li-Fraumeni Syndrome Education and Early Detection Clinic
Making a difference in quality of life and long-term survival through screening and education
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Introduction

Li-Fraumeni Syndrome (LFS) is a genetic cancer
predisposition syndrome that is defined as any
germline mutation in the TP53 tumor suppressor
gene. It is passed down in an autosomal dominant
pattern, with a 50% chance of passing the mutated
gene to each child. In response to stress signals, the
tumor suppressor gene controls a wide range of
processes including apoptosis, DNA replication and
repair, and regulatory control over the cell cycle.
When this gene is mutated, cells lack control over
these processes. There are two different types of
criteria used to diagnose LFS, the classical and the
Chompret criteria, which are defined by patients with
first degree relatives diagnosed with particular
cancers at certain ages. There are certain cancers
that are associated with LFS, and prevalence of
these cancers varies based on age. In the
pediatric/young adult population, risk is highest for
sarcomas, brain tumors, adrenocortical carcinoma,
leukemia, and early onset breast cancer. Cumulative
cancer risk associated with LFS has been estimated
to be approximately 50% by age 40 years and up to
90% by age 60 years.

Practice

The mission of the LEAD program at MDACC is to improve the patient experience, quality
of life, and long-term survival for children diagnosed with LFS by providing ageappropriate screening and supportive care services from professionals with LFS expertise
in a dedicated program.

Patients are recommended to follow regular
surveillance screening guidelines, which have been  This program provides a comprehensive evaluation and needs assessment for the LFS
pediatric population at MDACC. It is individualized to the patient with a multidisciplinary
shown to improve overall survival. Multiple screening
team offering health screening and supportive education. Individualized
guideline protocols are utilized, including that of the
recommendations and referrals are placed based on the assessment outcomes.
MD Anderson Children’s Cancer Hospital pediatric
LEAD clinic. LFS can have a significant physical and  Program services begin with a personal or family history of LFS. The patients are then
referred for genetic testing. If the testing indicates a germline TP53 mutation, then the
psychological impact on children and families that it
patient is referred to the LEAD clinic to begin screening.
effects.
 In the LEAD clinic, patients begin with an assessment and evaluation, including a
complete history and physical exam. They then undergo the appropriate screening
(including MRI whole body, MRI brain, ultrasounds, lab work, and dermatology
assessments). Patients are provided education on signs/symptoms to watch for,
lifestyle risk management and psychologic evaluation.
 If a malignancy is identified, patients are referred to the appropriate oncology team for
treatment. Screening for LFS continues during treatment, when possible.
 It can be challenging to get appropriate imaging approved with insurance companies, in
particular the MRI whole body, as they perceive screening to be investigational.
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Outcomes

At this time, 224 pediatric patients have been tested for
TP53 mutations at MDACC, and 34 have tested positive
for LFS. There are currently ~20 patients receiving care
in the MDACC pediatrics LEAD clinic. Of those 18, five
patients have received treatment for at least one
malignancy. Once a patient turns 21, they transition to
our adult LEAD clinic, as they focus on additional
malignancies that affect the adult population.
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